Biocon secures USFDA approval for generic Liraglutide, entering the lucrative US obesity treatment market with gSaxenda.

Biocon Ltd is quoting at Rs 394.6, up 0.99% on the day as on 12:44 IST on the NSE. The stock is up 26.54% in last one year as compared to a 13.13% jump in NIFTY and a 13.84% jump in the Nifty Pharma.

Biocon Limited on Thursday reported a 5.7-fold year-on-year (YoY) increase in consolidated net profit attributable to the ...

Motilal Oswal is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 450 in its research report dated 3, 2026.

Mittal said the opportunity remains meaningful despite the broader GLP-1 market shifting toward newer therapies such as ...

Biocon Limited ( (IN:BIOCON)) just unveiled an update. Biocon Limited has increased its ownership in its unlisted material subsidiary, Biocon Biologics Limited (BBL), to around 94% of BBL’s fully ...

Biotech firm Biocon on Thursday said it has raised ₹4,150 crore through a Qualified Institutions Placement (QIP) process. The ...

Zee Business analysts have shared a number of short- and long-term calls, including Tata Motors PV, Infosys, Dr Reddy’s, RVNL ...

Biocon posts 9% rise in Q3FY26 revenue to Rs 4,173 crore; net profit jumps to Rs 143.8 crore on strong generics and ...

Nuvama has flagged four pharma stocks as top ‘Buy’ picks, citing strong US launches, biosimilars traction and margin expansion with potential upside of up to 27% over the next year.

The Bengaluru-based company on 14 January said it raised $460 million via a QIP of shares to buy out Mylan Inc’s (Viatris) stake in its arm Biocon Biologics. Days later, it announced the acquisition ...